EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review

Mélanie Desaulniers iD, Étienne Rousseau iD, Kim M Pabst iD

British Journal of Radiology · 01.07.2026 · 99 (1183) · 1263-1270

DOI: 10.1093/bjr/tqaf020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Radiology, online erschienen am 05.02.2025. Verfasst von Mélanie Desaulniers und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, J1H 5H3, Canada. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Membrane Proteins, Neoplasms, Gelatinases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decade, fibroblast activation protein-α inhibitors (FAPIs), which target the cancer-associated fibroblasts of the tumour microenvironment, have become a topic of great interest. In oncology, FAPI PET/CT imaging has repeatedly demonstrated a higher lesion detection rate than other conventional imaging modalities such as CT or 18F-FDG PET/CT for several tumours. In some cases, the initial staging and therapeutic management may even change. Some FAPI radioligands may also be labelled with therapeutic radionuclides for theranostic applications. It is thus possible to treat certain metastatic cancers with FAPI radioligand therapy (FAPI-RLT), which is generally well tolerated with little toxicity. Recently, new FAPIs have been developed with the particularity of having a higher binding affinity for the target, which further improves the lesion detection rate on PET/CT and clinical outcomes following FAPI-RLT. This review provides recent updates in the clinical use of FAPI PET/CT and FAPI-RLT and discusses potential emergent applications, including in inflammation imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyMembrane ProteinsNeoplasmsGelatinasesHumansFibroblast Activation Protein AlphaRadiopharmaceuticalsSerine EndopeptidasesEndopeptidasesTumor Microenvironment

Stichwörter der Autor:innen

FAPI PETFAPI radioligand therapyfibroblast activation protein inhibitortheranostics

Substanzen

Fibroblast Activation Protein AlphaRadiopharmaceuticalsMembrane ProteinsGelatinasesSerine EndopeptidasesEndopeptidases

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, J1H 5H3, Canada.
  • Research Center of CHUS, CIUSSSE-CHUS, Sherbrooke, QC, J1H 5H3, Canada.
  • Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany.
  • Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, 45147, Germany.

ORCID-Profile: Mélanie Desaulniers, Étienne Rousseau, Kim M Pabst

Zitieren

APA

Desaulniers, M., Rousseau, É., & Pabst, K. M. (2026). Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review. British Journal of Radiology, 99(1183), 1263-1270. https://doi.org/10.1093/bjr/tqaf020

Vancouver

Desaulniers M, Rousseau É, Pabst KM. Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review. British Journal of Radiology. 2026;99(1183):1263-1270. doi:10.1093/bjr/tqaf020

BibTeX
@article{Desaulniers2026,
  author = {Desaulniers, Mélanie and Rousseau, Étienne and Pabst, Kim M},
  title = {Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review},
  journal = {British Journal of Radiology},
  year = {2026},
  volume = {99},
  number = {1183},
  pages = {1263--1270},
  doi = {10.1093/bjr/tqaf020}
}
Kostenlos starten →